Augmedix reports Q4 revenue $8.751M, consensus $8.51M.

Cash and restricted cash as of December 31, 2022, was $22.0 million compared to $41.6 million as of December 31, 2021. "We finished 2022 with our best-ever fourth quarter in terms of bookings, with sales momentum continuing into 2023 with record first-quarter bookings, including our largest-ever clinician cohort signed," said Manny Krakaris, Chief Executive Officer at Augmedix. "Our expanding portfolio of products has positioned us well for the large market opportunity in front of us, and we look forward to delivering strong results in 2023 with improving operating leverage." Continued Krakaris, "Our innovative technology is engineered to relieve the documentation burden for clinicians, allows the patient and doctor to truly connect at the point of care, and structures the visit data that ultimately improves future outcomes for patients and healthcare providers. We operate at the nexus of the critical issues impacting large health systems and U.S. healthcare overall, which are patient access, patient outcomes, and the cost curve. Helping health systems solve these big issues is leading to larger engagements and increased interest from both existing and new systems, as shown by our recent wins. Our development efforts are focused on delivering innovative products that can affect behavior at the point of care to drive better outcomes at scale so that we make a meaningful impact on the industry."